	ALTH AND HUMAN SERVICES RUG ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER 22215	DAYE(S) OF INSPECTION 10/29/2018-11/14/2018* FEI NUMBER 3014745182
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED George Martin Hiers IV, RPh, Owner	
Hiers Enterprises, LLC dba Northwest Compounding Pharmacy	1350 NE Stephens Street, Suite # 42
Roseburg, OR 97470-6410	Producer of sterile and non-sterile drug products

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, operators demonstrate inadequate technique during non-sterile to sterile production operations while in an unclassified zone and while under laminar airflow. For example:

- A) On 10/29/2018 during production of M.I.C B. Vitamins (25/50/1/1/1MG/ML Liquid) for IM injection, lot 10292018@15, formula ID: 6814, with a BUD of 01/27/2019, the Sterile Drug Tech was observed:
- -In an unclassified space, drug components were mixed and drawn from an unsterilized, (b) (4)into a sterile syringe. The syringe was then directly placed into an unsterilized (b) (4)container for final transport from the unclassified space into the ISO5 classified zone
- B) On 10/29/2018 during production of M.I.C B. Vitamins (25/50/1/1/1MG/ML Liquid), lot 10292018@15, formula ID: 6814, with a BUD of 01/27/2019, the Pharmacist in charge (PIC) was observed:
- -Transporting in-process drug product in a sterile syringe via an unsterilized (b) (4):ontainer from the unclassified zone into the ISO8 classified anteroom while donning non-sterile gloves. In-process product in (b) (4) was placed on a cardboard box used as storage in the ISO8 classified anteroom.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Bryan L Mcguckin,	Bryan I. I Investor	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 1 of 9 PAGES

		TH AND HUMAN SERVICE G ADMINISTRATION	ES			
DISTRICT ADDRESS AND PHO	NE NUMBER	DATE(S) OF INS				
[[[[[[] [[] [[] [[] [] [] [] [] [] [] []	ve SE Suite 210	10/29/	2018-11/14/2018	*		
Bothell, WA		FEINUMBER 301474	5182	5.50		
(425) 302-034	0 Fax: (425)302-0404		0102	1		
NAME AND TITLE OF INDIVIDU	AL TO WHOM REPORT ISSUED	- N	X			
177	n Hiers IV, RPh, Owner					
FIRM NAME		STREET ADDRESS				
	rises, LLC dba Northwest	1350 NE Stephens	s Street, Suit	e # 42		
Compounding COTY, STATE, ZIP CODE, COUN	Pharmacy	TYPE ESTABLISHMENT INSPECTED				
Roseburg, OR		Producer of ster	rile and non-st	erile drug		
hair net and non- -Non-sterile glov	classified anteroom the PIC proceeded sterile face mask. res were used to open the door leading is container with the in-process product	into the ISO 7 classifie	d buffer zone.			
classified buffer	zone.					
-Equipment (rack without glov	(b) (4)) was removed from twes being disinfected after.	the ISO5 classified hoo	od and placed on top	of a storage		
requires (b which has not be calibration or ser	which has not been validated. This equipment was last calibrated on 11/16/2004 with no other record of calibration or service provided to ensure the equipment is operating as designed. There is no biological indicator used and there is no load pattern to reference. Sterility testing is not performed on the Hydroxyprogesterone					
D) Equipment wa area without bein	9	(b) (4)) in stages and	charged into the IS	O 5 classified		
E) Dynamic smo adequate review.	ke studies have not been conducted. Sn	noke studies conducted	l lack appropriate da	ata necessary for		
F) A recognized sterile drug produ	(b) (4) such as " ucts using a (b) (4) process.	(b) (4)" is not condu	cted following the p	roduction of		
G) Media fills are conducted (b) (4) but do not include the most challenging process performed.						
SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Bryan L Mcguckin, Investigat	ior	Bryan I. Mogustán Innschjator Signad Byr Bryan I. Micgustán -3 Osto Signad: 11-14-2018 08:50:30	DATE ISSUED 11/14/2018		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	SPECTIONAL OBSERVATION	ONS	PAGE 2 of 9 PAGES		

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
22215 26th Ave SE Suite 210	10/29/2018-11/14/2018*			
Bothell, WA 98021	FEINUMBER			
(425)302-0340 Fax: (425)302-0404	3014745182			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
George Martin Hiers IV, RPh, Owner				
FIRM NAME	STREET ADDRESS			
Hiers Enterprises, LLC dba Northwest	1350 NE Stephens Street, Suite # 42			
Compounding Pharmacy				
CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED				
Roseburg, OR 97470-6410 Producer of sterile and non-sterile dru products				

OBSERVATION 2

Clothing of personnel engaged in the of drug products is not appropriate for the duties they perform.

Specifically,

During production on 10/29/2018 of Glutathione Sterile 100MG/ML Solution, Lot: 10292018@17, formula ID: 10586, with a BUD of 01/27/2019, the following was observed:

- -The Pharmacist in charge was observed to don a previously worn, non-sterile gown hanging on the wall of the ISO 8 classified anteroom that was ill fitting, exposing both skin (unshaven neck and eyes without cover) and personal clothing inside the ISO5 classified LAFH during production.
- The Pharmacist in charge was observed leaning into the ISO5 classified LAFH during aseptic processing with other non-sterile garbing such as gloves, face mask and hairnet.

OBSERVATION 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, the ISO classified areas lack appropriate data to support appropriate installation certification and continued ISO classifications.

A) On 10/29/2018 a ceiling tile was observed to be loose in the ISO7 classified buffer zone, exposing sterile drug production areas to unclassified air. Additionally, on 11/01/2018 the HEPA system was viewed via an adjacent

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Bryan L Mcguckin,	Investigator	Oryan L Moquetin Investigator Signed By: Oryan L Moquetin -S Diese Signed: 11-14-2018 065638	DATE ISSUED 11/14/2018
FORM FDA 483 (09408)	DECUME EDITION OR OF LETT.	INSPECTIONAL ORSEDVATION	ONE	PAGE 3 40 BAGES

	DEPARTMENT OF HEAL	TH AND HUMA G ADMINISTRATION		ES		
DISTRICT ADDRESS AND PHO	E NUMBER		DATE(S) OF INS			
Bothell, WA	ve SE Suite 210		10/29/ FEI NUMBER	2018-11/14/2018	<u>}</u> *	
	10 Fax: (425) 302-0404		301474	5182		
NAME AND TITLE OF INDIVIDUA						
	Hiers IV, RPh, Owner					
FIRM NAME	. HIELS IV, KIII, OWNEL	STREET ADDRESS				
Hiers Enterpart Compounding I	rises, LLC dba Northwest Pharmacy					
Roseburg, OR		Producer products		rile and non-st	erile drug	
unclassified area.	Openings were observed in the light fi	xture that wo	ould allov	v unclassified air int	to the	
prevent or detect	I monitoring of ISO classified zones is incursion into the ISO classified zones rocesses has ever been conducted. EM	is not ongoin	ng at you	facility and no risk		
	nitoring does not include samples taken action inside the ISO5 classified zone a		oved hand	ls of employees afte	r performing	
	of data to support adequate pressure of data to support adequate pressure of prior to aseptic filling operations. Pressured.					
•						
OBSERVATION Aseptic process equipment to pr	ON 4 ing areas are deficient regarding the oduce aseptic conditions.	system for	cleaning	and disinfecting	the room and	
Specifically,				s		
A) Non-sterile (b) (4) is used for the cleaning and san	itation of the	ISO alaa	sified zones This	(b) (4) :-	
diluted from	(b) (4). No procedures were p	rovided to de	monetrate	how sold dilution	is conducted	
W/ 40 1/2/06 1/2	demonstrate (b) (4) concentration is		monstrate	a now said dilution	is conducted nor	
data provided to	demonstrate (b) (4) concentration is	acilieveu.				
B) Non-sterile wi	pes are used to clean the ISO5 classifie	d zone.				
					8	
1 - 10-1	EMPLOYEE(S) SIGNATURE				DATE ISSUED	
SEE REVERSE OF THIS PAGE	Bryan L Mcguckin, Investigat	or.		SCHOOLS	11/14/2018	
OF THIS PAGE				Bryan I. Moguckin Investigator Signed By: Bryan I. Moguckin -S Date Skoned: 11-14-2018 08-58-36		
				<u> </u>		

INSPECTIONAL OBSERVATIONS

PAGE 4 of 9 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHON	E NUMBER	Z-1163-205-15-13-11-12	DATE(S) OF INSPECTION		
Bothell, WA	ve SE Suite 210		10/29/2018-11/14/2018*		
	5)302-0340 Fax: (425)302-0404		3014745182		
NAME AND TITLE OF INDIVIDUA					
FIRM NAME	Hiers IV, RPh, Owner	STREET ADDRESS	5		
Hiers Enterp	rises, LLC dba Northwest	1350 NE	Stephens Street, Suite # 42		
Compounding I					
		TYPE ESTABLISHM			
Roseburg, OR	97470-6410	products	r of sterile and non-sterile drug		
C) Your firm is using " (b) (4) as a sporicidal agent. No data was provided to establish the effectiveness of (b) (4) as a sporicidal disinfectant and no dwell time has been established or proceduralized. D) Your firm is using sponges and green scratch pads to clean equipment such as beakers, stirring rods, raw ingredient storage containers and measuring utensils used in the production of sterile drug products. The sanitation of equipment used in the production of sterile drug products is purportedly conducted using (b) (4) however there is no procedure to demonstrate an adequate process and no record is kept of instrument cleaning or sanitation. E) Walls and ceiling design of the ISO classified zones are not constructed of a smooth, easily cleanable surface to allow for adequate sanitation.					
OBSERVATION 5 There is no written testing program designed to assess the stability characteristics of drug products. Specifically, the Beyond Use Dates (BUD) extended or otherwise used at your facility, are not associated with any appropriate study intended to demonstrate the stability of finished drug products for characteristics such as potency or sterility. M.I.C B. Vitamins (25/50/1/1/1MG/ML Liquid) lot:10292018@15 for IM injection, formula ID: 6814, produced on 10/29/2018 was assigned a BUD of 01/27/2019 (90 Days). When asked to provide the source of data for assigning said BUD's the "Pharmacist In Charge" downloaded a formula sheet from (b) (4) website. The firm is currently not following (b) (4) suggested formula processes or guidelines as recommended. Furthermore, under (b) (4) formula provided guidelines, in the absence of passing a sterility test under high-risk conditions (non-sterile to sterile) storage periods cannot exceed the following time periods:					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Bryan L Mcguckin, Investiga	tor	DATE ISSUED 11/14/2018 Dryan L Megudah Investigator Sever Gyr Dryan L Megudah 3 X X		

INSPECTIONAL OBSERVATIONS

PAGE 5 of 9 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

	ALTH AND HUMAN SERVICES RUG ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
22215 26th Ave SE Suite 210	10/29/2018-11/14/2018*
Bothell, WA 98021	FEINUMBER
(425)302-0340 Fax: (425)302-0404	3014745182
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
George Martin Hiers IV, RPh, Owner	
FIRM NAME	STREET ADDRESS
Hiers Enterprises, LLC dba Northwest Compounding Pharmacy	1350 NE Stephens Street, Suite # 42
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Roseburg, OR 97470-6410	Producer of sterile and non-sterile drug products

- -Controlled Room Temp (not more than (b) (4))
- -Cold Temp (not more than (b) (4).)

Referenced literature to support current and extended BUD's is neither associated with your current processes nor associated with finished drugs packaged inside your firm's container closure system.

-There is no data to support any of your BUD's with current processes or practices.

OBSERVATION 6

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically, the firm has not established a testing program for any of its sterile drug products in order to regularly demonstrate products are sterile and pyrogen free.

OBSERVATION 7

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

Specifically, microbial limits have not been established for non-sterile finished drug products produced at your facility and products are not tested for the presence of objectionable microorganisms.

SEE REVERSE OF THIS PAGE	Bryan L Mcguckin, Inv	vestigator	Bryan I, Moguskin Investigation Signed Dy Bryan I, Moguskin - 3 Data Signat: 11-14-2018 0336230	DATE ISSUED 11/14/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	NC .	PAGE 6 of 9 PAGES

	한 경기 가장	TH AND HUMAN SERVICE G ADMINISTRATION	ES	
DISTRICT ADDRESS AND PHO	NE NUMBER	DATE(S) OF INS		- 282
Bothell, WA	ve SE Suite 210 98021	FEI NUMBER	2018-11/14/2018	*
	0 Fax: (425)302-0404	301474	5182	
NAME AND TITLE OF INDIVIDU	IAL TO WHOM REPORT ISSUED			
	n Hiers IV, RPh, Owner	NO. 100 Aug.		
FIRM NAME	TIG dhe Nouthwest	STREET ADDRESS	- Guit	1 40
	rises, LLC dba Northwest Pharmacy	1350 NE Stephens	s Street, Sulc	e # 42
Compounding I		TYPE ESTABLISHMENT INSPECTED		
Roseburg, OR	97470-6410	Producer of ster products	rile and non-st	erile drug
	W			
OBSERVATION	ON 8			
	ease of drug product for distribution	do not include appro	opriate laboratory	determination
	conformance to the final specification			
prior to release.		Allo with the same	mongai or tall	
Specifically, you	ar firm does not conduct any potency	testing of sterile or no	on-sterile drug produ	ucts produced at
your facility. No	records could be provided to demonstr	ate established accepta	ince criteria data.	Factor
				ļ
		192 - 192 - 10 Th		
OBSERVATIO		1000 ID (20)		er 100 20000 gg/
	emponent that is liable to microbiolo		that is objectionab	le in view of
its intended use	is not subjected to microbiological	tests before use.		
Carifically				
Specifically,				
A) (b) (4	1) used in the production of sterile and r	non-sterile drug produc	ets is not tested before	re use for the
1,1,1,0 % / 1	obiological contamination. The (b) (4)c			
extracted using a				
gallon container		in an unclassified zon		
For example:		The same of the same		
2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3				
	during production of Glutathione Sterile			-
	JD of 01/27/2019, the Sterile Lab Tech	was observed using (D) (4) stored in the	(b) (4)
as an ingre	dient.			
l				
l				
50 <u>50 50 50 50 50 50 50 50 50 50 50 50 50 5</u>	45 ASS			
	EMPLOYEE(S) SIGNATURE			DATE ISSUED
SEE REVERSE	Bryan L Mcguckin, Investigat	tor	1	11/14/2018
OF THIS PAGE			Bryan L Moguckin Investigator Signed By: Bryan L. Moguckin - S Data Signed: 11-14-2018 08:59:36	
			X Dizo Signed: 11-14-2018 (4:30-30	15
		3.40		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	SPECTIONAL OBSERVATION	ONS	PAGE 7 of 9 PAGES

	FOOD AND DRUG	I H AND HUMAN SERVICE ADMINISTRATION	iS .	
DISTRICT ADDRESS AND PHON		DATE(S) OF INSI		20
Bothell, WA 9	e SE Suite 210	10/29/2 FEINUMBER	2018-11/14/2018	*
	Fax: (425) 302-0404	3014745	5182	
(425)502 0540	Tax. (425/502 0404	70 a fine stand on the standard 70		
NAME AND TITLE OF INDIVIDUA	L TO WHOM REPORT ISSUED			_
George Martin	Hiers IV, RPh, Owner			
FIRM NAME		STREET ADDRESS		
	ises, LLC dba Northwest	1350 NE Stephens	Street, Suit	e # 42
Compounding P	harmacy	TYPE ESTABLISHMENT INSPECTED		
Roseburg, OR				
Roseburg, OK	97470-6410	Producer of ster	rile and non-st	erile arug
		products		
-On 10/29/2018 d	uring production of M.I.C B. Vitamins	(25/50/1/1/1MG/ML	Liquid) for IM injec	ction lot
	ormula ID: 6814, with a BUD of 01/27		553 252	5 12 2
	= 10 m (Colored - 10 m) : 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	2019, the Sterne Drug	, recir was observed	using (=) (-)
stored in the	(b) (4) as an ingredient.			
O- 10/21/2019 d		-1-4' 1-4 102020104	220 C 1 ID 10	(61 - 14 - DVID
	uring production of Fluorouracil 2% S			
of 04/28/2019, the	e lab technician was observed using (b)	(4) from the	(b) (4) as ar	n ingredient.
D) 0 10/00/0016			6	(b) (4)a
	during the production of sterile drug			(b) (4)for
	(4)manufactured by	(b) (4), was observed	stored and uncapped	d on top of the
LAFH.				7/2-
Control Control Control Control Control				
		•		
A			32-3	4
OBSERVATIO	N 10			
Aseptic process	ing areas are deficient regarding air	supply that is filtered	d through high-eff	iciency
S. S	Iters under positive pressure.	,		
i F asar Madaluman Sanara Tara I				
Specifically your	ISO classified zones lack sufficient da	ata to substantiate the o	urrent classification	s For evample:
Specificany, your	150 classified zones lack sufficient de	na to substantiate the c	diffent classification	is. For example.
-Validation of vo	ur HEPA system has never been condu	cted.		
				8:
- (b) (4) HEPA	integrity testing results do not provide	adequate data to suppo	ort ongoing qualifica	ation of your
system.				6040
	ent used in your aseptic processing are			
not designed to m	aintain ceiling integrity and prevent in	filtration of particulate	into the clean room	under positive
pressure.				
	EMPLOYEE(S) SIGNATURE			DATE ISSUED
SEE REVERSE	Bryan L Mcguckin, Investigat	tor	ľ	11/14/2018
OF THIS PAGE	group = novem man response remainment of the transfer and for the		Bryan L Moguctin Investigator	
			Signed By: Bryan L. Meguctón -S Dato Signed: 11-14-2018 08:50:30	
			-	
			1	

INSPECTIONAL OBSERVATIONS

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

PAGE 8 of 9 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION						
DISTRICT ADDRESS AND PHON	IE NUMBER	DATE(S)	OF INSPECTION			
22215 26th Av Bothell, WA 9	re SE Suite 210	10/	29/2018-11/14/2018 WBER	*		
	Fax:(425)302-0404		4745182			
NAME AND TITLE OF INDIVIDUA						
George Martir	Hiers IV, RPh, Owner	STREET ADDRESS	·			
	rises, LLC dba Northwest	i	hens Street, Suit	~ # 12		
		TOO NE OCCE.	Hella Street, Dart	е п ч.с		
Compounding E		TYPE ESTABLISHMENT INSPE				
Roseburg, OR	97470-6410	Producer of products	sterile and non-st	erile drug		
*DATES OF INSPECTION 10/29/2018(Mon), 10/30/2018(Tue), 10/31/2018(Wed), 11/01/2018(Thu), 11/14/2018(Wed)						
	Lever are a series and					
SEE REVERSE	EMPLOYEE(S)SIGNATURE Bryan L Mcguckin, Investig	ator	1	DATE ISSUED 11/14/2018		
OF THIS PAGE	Dijan i noguenin, investig	401	Bryan L Mcguddin	11/11/2010		
ł			Bryan I, Moguckin Investigator Signed By: Bryan L. Moguckin -S Date Signed: 11-14-2018 08:56:36			
FORM PD 4 (22 (22 TO		NODECTION AL OBORD	VATIONS	DACE 0 -40 DACE		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE I	NSPECTIONAL OBSER	VALIUNS	PAGE 9 of 9 PAGES		